Grant: Engage Grants Program
École Polytechnique de Montréal
$25,000.00
Next-generation of Transforming Growth Factor ß inhibitors
EF 2017-18
Résumé
Transforming growth factor beta (TGF-ß) is a pleiotropic cytokine with essential roles in normal embryonicdevelopment and tissue homeostasis. The role of excessive TGF-ß action in fibrosis is well documented.Therefore, it is of interest to develop drugs that block TGF-ß signaling for therapeutic benefit. This therapeuticniche is now being explored by Formation Biologics, a Canadian company focusing on the development ofTGF-ß inhibitors. Formation has a successful drug development record with one product in phase I clinicaltrials, and a second in IND-enabling development. To continue its efforts in the development of specific TGF-ßinhibitors (i.e. specific to each isoform within the TGF-ß superfamily), Formation Biologics is now interestedin exploring promising alternatives to antibody-based therapeutics. The proposed research thus focuses onharnessing the TGF-ß-neutralizing potential of TGF-ß receptor extracellular domains to develop potent TGF-ßantagonists. More specifically, the proposal is to physically combine various receptor extracellular domains toimprove their TGF-ß binding and sequestration efficiency while taking advantage of their binding specificity. Ifperformed with a classical experimental approach (i.e., the design of chimeric proteins corresponding to thefusion of two distinct receptors, their purification and related assays), such a study would be extremelytime-consuming if one considers the number of TGF-ß isoforms, the number of receptors they bind to, as wellas the number of resulting receptor combinations. Using a unique molecular adaptor strategy emanating fromprevious work performed in De Crescenzo's lab, the inhibition of TGF-ß signaling by different TGF-ß receptorcombinations will be tested more rapidly by setting an innovative mix-and-match strategy. The expectedoutcome is a competitive and novel strategy to inhibit TGF-ß signaling. Successful completion of this projectwill provide Formation Biologics with a new therapeutic avenue to inhibit TGF-ß signaling, hence promotingthe development of new drugs, and thus directly benefiting the Canadian patient population and economy.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
520583-2017
Name nom
DeCrescenzo, Gregory
Department département
Génie chimique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
1
Nb partie
1
Application title
Next-generation of Transforming Growth Factor ß inhibitors
Keyword
NSERC
Application summary
Transforming growth factor beta (TGF-ß) is a pleiotropic cytokine with essential roles in normal embryonicdevelopment and tissue homeostasis. The role of excessive TGF-ß action in fibrosis is well documented.Therefore, it is of interest to develop drugs that block TGF-ß signaling for therapeutic benefit. This therapeuticniche is now being explored by Formation Biologics, a Canadian company focusing on the development ofTGF-ß inhibitors. Formation has a successful drug development record with one product in phase I clinicaltrials, and a second in IND-enabling development. To continue its efforts in the development of specific TGF-ßinhibitors (i.e. specific to each isoform within the TGF-ß superfamily), Formation Biologics is now interestedin exploring promising alternatives to antibody-based therapeutics. The proposed research thus focuses onharnessing the TGF-ß-neutralizing potential of TGF-ß receptor extracellular domains to develop potent TGF-ßantagonists. More specifically, the proposal is to physically combine various receptor extracellular domains toimprove their TGF-ß binding and sequestration efficiency while taking advantage of their binding specificity. Ifperformed with a classical experimental approach (i.e., the design of chimeric proteins corresponding to thefusion of two distinct receptors, their purification and related assays), such a study would be extremelytime-consuming if one considers the number of TGF-ß isoforms, the number of receptors they bind to, as wellas the number of resulting receptor combinations. Using a unique molecular adaptor strategy emanating fromprevious work performed in De Crescenzo's lab, the inhibition of TGF-ß signaling by different TGF-ß receptorcombinations will be tested more rapidly by setting an innovative mix-and-match strategy. The expectedoutcome is a competitive and novel strategy to inhibit TGF-ß signaling. Successful completion of this projectwill provide Formation Biologics with a new therapeutic avenue to inhibit TGF-ß signaling, hence promotingthe development of new drugs, and thus directly benefiting the Canadian patient population and economy.